Longevity Research
BrightCore provides AI-driven platform for drug discovery to extend healthy human lifespan.
BrightCore joins XPRIZE Healthspan global competition
BrightCore joined XPRIZE Healthspan global competition in January 2024, with the goal of discovering an accessible therapeutic that increases healthy human lifespan.
Applying AI and molecular dynamics to identify potential mTOR inhibitors
mTOR inhibition has been identified as a mechanism for extending lifespan in mice, and as a target for aging intervention in humans. To find novel drug candidates, we run our pre-trained deep learning AI models through Enamine REAL database, one of the largest chemical spaces with molecules that can be readily synthesized for further in-vitro testing.
Deploying BrightCore AI platform to find inhibitors of the SARS-CoV-2 replicase polyprotein
Age is the most significant factor in the COVID-19 disease outcomes, and its mortality risk profile is similar to age-related diseases. Finding potential drug candidates for cellular and immune system rejuvenation is an additional pathway for COVID-19 therapeutics, and we are exploring targets for potential intervention.